Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

Drexel University7 enrolled

Overview

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Epilepsy Magnesium Deficiency Vitamin D Deficiency

Interventions

No Intervention. Study is Cross Sectional in natureOTHER

No Intervention. Study is cross sectional in nature

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals receiving anti-epileptic drugs as a treatment for epilepsy Exclusion Criteria: * Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.

Locations (2)

Drexel University Nutrition Sciences Research Lab

Philadelphia, Pennsylvania, United States

Drexel University

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Bone mineral density

Will be measured at Tibia, Hip and Total Body using a DXA scan

Time frame: 1 time point - baseline

Secondary Outcomes

Ionized Magnesium in serum

This will be assayed in the serum

Time frame: 1 time point - baseline

Vitamin D - 25 hydroxy vitamin D

This will be assayed in the serum

Time frame: 1 time point - baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.